Phase Ib trial of reformulated niclosamide with abiraterone/prednisone in men with castration-resistant prostate cancer
- Standort
-
Deutsche Nationalbibliothek Frankfurt am Main
- ISSN
-
2045-2322
- Umfang
-
Online-Ressource
- Sprache
-
Englisch
- Anmerkungen
-
online resource.
- Erschienen in
-
Phase Ib trial of reformulated niclosamide with abiraterone/prednisone in men with castration-resistant prostate cancer ; volume:11 ; number:1 ; day:18 ; month:3 ; year:2021 ; pages:1-7 ; date:12.2021
Scientific reports ; 11, Heft 1 (18.3.2021), 1-7, 12.2021
- Urheber
-
Parikh, Mamta
Liu, Chengfei
Wu, Chun-Yi
Evans, Christopher P.
Dall’Era, Marc
Robles, Daniel
Lara, Primo N.
Agarwal, Neeraj
Gao, Allen C.
Pan, Chong-Xian
- Beteiligte Personen und Organisationen
-
SpringerLink (Online service)
- DOI
-
10.1038/s41598-021-85969-x
- URN
-
urn:nbn:de:101:1-2022111209232812606083
- Rechteinformation
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Letzte Aktualisierung
-
15.08.2025, 07:38 MESZ
Datenpartner
Dieses Objekt wird bereitgestellt von:
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Beteiligte
- Parikh, Mamta
- Liu, Chengfei
- Wu, Chun-Yi
- Evans, Christopher P.
- Dall’Era, Marc
- Robles, Daniel
- Lara, Primo N.
- Agarwal, Neeraj
- Gao, Allen C.
- Pan, Chong-Xian
- SpringerLink (Online service)
Ähnliche Objekte (12)
Chemotherapy management for unfit patients with metastatic castration-resistant prostate cancer
Targeting molecular resistance in castration-resistant prostate cancer
Evolving Personalized Therapy for Castration-Resistant Prostate Cancer
Osteoclasts directly influence castration-resistant prostate cancer cells
Treatment patterns and characteristics of European patients with castration-resistant prostate cancer
Castration-resistant prostate cancer patient presenting with whole genome doubling with CDK-12 mutation
Effect of simvastatin on castration-resistant prostate cancer cells
Ureter metastatic castration-resistant prostate cancer: a case report
Nonmetastatic Castration-Resistant Prostate Cancer: Current Challenges and Trends
Olaparib-Induced Purpuric Drug Eruption in a Patient with Castration-Resistant Prostate Cancer
Physician preferences for non-metastatic castration-resistant prostate cancer treatment
Ailanthone: a new potential drug for castration-resistant prostate cancer
Chemotherapy management for unfit patients with metastatic castration-resistant prostate cancer
Targeting molecular resistance in castration-resistant prostate cancer
Evolving Personalized Therapy for Castration-Resistant Prostate Cancer
Osteoclasts directly influence castration-resistant prostate cancer cells
Treatment patterns and characteristics of European patients with castration-resistant prostate cancer
Castration-resistant prostate cancer patient presenting with whole genome doubling with CDK-12 mutation
Effect of simvastatin on castration-resistant prostate cancer cells
Ureter metastatic castration-resistant prostate cancer: a case report
Nonmetastatic Castration-Resistant Prostate Cancer: Current Challenges and Trends
Olaparib-Induced Purpuric Drug Eruption in a Patient with Castration-Resistant Prostate Cancer
Physician preferences for non-metastatic castration-resistant prostate cancer treatment
Ailanthone: a new potential drug for castration-resistant prostate cancer
Chemotherapy management for unfit patients with metastatic castration-resistant prostate cancer
Targeting molecular resistance in castration-resistant prostate cancer
Evolving Personalized Therapy for Castration-Resistant Prostate Cancer
Osteoclasts directly influence castration-resistant prostate cancer cells
Treatment patterns and characteristics of European patients with castration-resistant prostate cancer
Castration-resistant prostate cancer patient presenting with whole genome doubling with CDK-12 mutation
Effect of simvastatin on castration-resistant prostate cancer cells
Ureter metastatic castration-resistant prostate cancer: a case report
Nonmetastatic Castration-Resistant Prostate Cancer: Current Challenges and Trends
Olaparib-Induced Purpuric Drug Eruption in a Patient with Castration-Resistant Prostate Cancer
Physician preferences for non-metastatic castration-resistant prostate cancer treatment